Kailera Therapeutics

Kailera Therapeutics is an obesity therapeutics biotechnology company that develops biotechnology medicines for people living with obesity. It built its drug pipeline through an in-licensing collaboration with Hengrui. Its lead product candidate, ribupatide, is a GLP-1/GIP receptor dual-agonist peptide developed in injectable and oral formulations.

Kailera's approach spans incretin-based candidates across oral and injectable formulations and multiple receptor mechanisms, including oral small-molecule GLP-1 agonist KAI-7535 and injectable GLP-1/GIP/glucagon tri-agonist KAI-4729. It holds exclusive development and commercialization rights outside China, Hong Kong, Macau and Taiwan. The company targets people living with obesity, including those with a higher BMI who need medications offering greater weight loss.